John Crosby, MD
Interventional Pain Medicine · Baton Rouge, LANPI 1891783072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Abbott at 35.5% of the total. Reporting peaked in 2019 at $1,558 and has fallen 65.3% since, to $540 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in LA, where the typical reported total is $4,761.
Across 207 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Collegium Pharmaceutical, Inc.$689
- Scilex Pharmaceuticals Inc.$335
- Boston Scientific$308
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$280
- Valinor Pharma, LLC$275
- plus $1K from 25 others
What the payments were for
- Travel & lodging$3738%
- Food & beverage$4,24392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 57 | $1,640 |
| Collegium Pharmaceutical, Inc. | 37 | $689 |
| Scilex Pharmaceuticals Inc. | 19 | $335 |
| Boston Scientific | 6 | $308 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $280 |
| Valinor Pharma, LLC | 20 | $275 |
| Si-bone, Inc. | 2 | $150 |
| Nevro Corp. | 3 | $123 |
| Biodelivery Sciences International, Inc. | 7 | $85 |
| Forte Bio-pharma LLC | 6 | $83 |
| Bioventus LLC | 2 | $59 |
| Lifeward, Inc. | 3 | $52 |
| Ossur Americas, Inc. | 1 | $49 |
| Zyla Life Sciences, Inc. | 3 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Saluda Medical Americas, Inc. | 1 | $41 |
| Pacira Therapeutics, Inc. | 2 | $41 |
| Redhill Biopharma Inc. | 2 | $38 |
| Medtronic | 2 | $36 |
| Nalu Medical, Inc. | 2 | $32 |
| Kaleo, Inc. | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Amgen | 2 | $25 |
| Globus Medical | 1 | $24 |
| Vertex | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Sentynl Therapeutics, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,616 in reported general payments places this provider in the 45th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,630 | $104,058 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,406 | $69,791 |
| RelistorMethylnaltrexone Bromide | 29 | $67,557 |
| ZtlidoLidocaine | 50 | $49,375 |
| BelbucaBuprenorphine Hcl | 47 | $40,441 |
| MovantikNaloxegol Oxalate | 73 | $30,575 |
| Xtampza ErOxycodone Myristate | 42 | $29,214 |
| OxycontinOxycodone Hcl | 45 | $18,810 |
| Lidocaine | 183 | $17,698 |
| Gabapentin | 1,401 | $15,199 |
| Tramadol Hcl | 1,456 | $13,677 |
| SymproicNaldemedine Tosylate | 30 | $13,286 |
| Oxycodone Hcl | 685 | $12,420 |
| Pregabalin | 430 | $9,672 |
| Diclofenac Sodium | 200 | $7,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $689 | $69,65589 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $280 | $67,55729 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $335 | $49,37550 claims |
| Redhill Biopharma Inc.Movantik | $38 | $30,57573 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Baton Rouge
- Adam CarinciBaton Rouge$17K
- Jihad JihaBaton Rouge$17K
- Kelly BoussertBaton Rouge$9K
- Gary McDanielBaton Rouge$9K
- John BraswellBaton Rouge$8K
- Sean GrahamBaton Rouge$5K
- Alpesh PatelBaton Rouge$4K
- Joseph TurnipseedBaton Rouge$4K
- Allison WalkerBaton Rouge$2K
- John BurdineBaton Rouge$177
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.